comprehensive -WSS

comprehensive

author：comprehensive 2025-09-04 04:27:14 - browse：533

Patient treated with Impella in the heart. -- health tech coverage from STAT — Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. Business Wire

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed.

Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. The FDA published a warning letter on Wednesday telling the company it should have submitted its software for approval before putting it on the market. The agency also took issue with Abiomed’s failure to report various problems with its heart pumps.

The letter comes a year after the Food and Drug Administration announced its intention to regulate more health software tools, sending the industry into an uproar.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Mississippi candidates for statewide offices square off in party primaries

explore

WSS

Judges halt a Biden rule offering student debt relief for those alleging colleges misled them

As biotech industry slumps, bioscience job market is upside down

Disappointing trial forces Pfizer to pivot on obesity medicine plans

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

What don’t we know about an Alzheimer’s drug side effect?

Despite FDA concern, risk that CAR

Wikipedia

comprehensive

focus

New air purifier tech could be key to improving indoor air quality

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

After affirmative action ruling, medical educators look to 'holistic review'

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

Heart attack and stroke risk calculators need revising

Judges halt a Biden rule offering student debt relief for those alleging colleges misled them

23andMe had bad news about my health. I wish a person had delivered it

ReNAgade cuts staff seven months after raising $300 million

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Trump Jan. 6 attorney John Lauro is ex

leisure time

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

Cigna, Humana reportedly in talks to merge

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

hotspot

Wikipedia

explore

focus